Project Details
Description
Dr. Hayek is the Vice President and Chief Transformation Officer, and Associate Professor
of Internal Medicine at the University of Texas Medical Branch, an Adjunct Professor at the
University of Michigan, the Senior Advisor of Cohort Development for the Precision Health
Initiative (PHI) and the former Medical Director of the Frankel Cardiovascular Center Clinics
at the University of Michigan. He is an NIH-funded translational physician-scientist with
expertise in biomarker research, risk prediction and large cohort studies, and has over 200
peer-reviewed publications, many in the highest impact journals as lead or senior author
(New England Journal of Medicine, Nature Medicine, JCI, JASN amongst others). Dr. Hayek's
research spans the methodologic spectrum of bench to bedside research, from the
development of experimental models, use of novel biomarkers, cohort development and
biobanking, to clinical trials, with a notable focus on the cardio-renal axis. He was the
principal investigator of the Michigan Medicine Covid-19 Cohort (M2C2), a prospective
cohort and biobank which includes over 4000 patients and 8000 biological samples which
contributed greatly to our understanding of the relationship between Covid-19 and kidney
injury.
Dr. Hayek's expertise in the cardio-renal axis and experience with the logistical aspects of
cohort development and biobanking will allow him to successfully direct the Resource
Development Core (RDC). Dr. Hayek will be responsible for the oversight of RDC activities,
including assisting prospective users of the core in developing their proposal, establishing
workflows, coordinating between the different components of the RDC, Applied Systems
Biology Core (ASBC), and Data Analytic Services Core (DASC), evaluating QA/QC metrics,
and assessing progress to ensure milestones are met.
Status | Finished |
---|---|
Effective start/end date | 3/1/24 → 9/30/24 |
Funding
- University of Michigan ( Award #5U54DK13731402): $25,152.00